| Revenue Growth | Americas sleep devices up 8%; Rest of World sleep devices up 13%. |
|---|---|
| Mgmt Confidence | High confidence in 2030 strategy and high-single-digit long-term revenue growth. |
| Demand Visibility | Strong top-of-funnel demand from GLP-1 awareness and wearable sleep tracking. |
| Margin Trends | Gross margin 62.3%, up 90bps YoY; FY2027 low double-digit expansion expected. |
| Op. Leverage | Operating margin 35.2%; 180bps expansion in FY2026; slight expansion guided FY2027. |
| Pricing Power | Implementing very modest price increases to offset inflation in components and freight. |
| Vol vs Price | Growth is predominantly volume-led; price increases described as very modest. |
| Segment Growth | Masks grew 10% in Americas; Residential Care Software expected high-single-digit growth. |
| New Clients | Oura partnership drove 13,000 users to ResMed; 75% identified as undiagnosed. |
| Capex & Debt | Acquired Noctrix; divesting MatrixCare; $160M-$180M Capex; $1.5B share buyback planned. |
| Regulatory | Astral field safety corrective action; $42M provision taken for expected costs. |
| Commentary | Focusing on 'active portfolio management' by divesting non-core assets like MatrixCare. |
| New Launches | AirSense 11 China launch; AirCurve 11 ST/STA; AirFit F40 fabric mask. |
Growth
FY2026 revenue grew 10% to $4.7 billion; non-GAAP EPS rose 17%.
Outlook
FY2027 revenue guidance of $5.75B-$5.85B; returning over $1.85B to shareholders via buybacks and dividends.
Risks
Astral field safety notice creates a $75 million revenue headwind and 15-cent EPS drag in FY2027.
The company's earnings call, NYSE: RMD, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Resmed Inc: key numbers
- Share price
- $238.19Close, Nov 16
- Market cap
- $33.5B
- Shares outstanding
- 140.66MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Resmed Inc
All →Resmed Chairman and CEO Michael J. Farrell Sells $1.18M of Stock
Michael J. Farrell, Chairman and CEO, sold 4,993 shares of Resmed Inc at $235.35 a share, worth $1.18M in total on Nov 9, 2026. Shares held after the trade: 479,803 (-1.0%).
- Value
- $1.18M
- Shares
- 4,993
- Price
- $235.35
- Role
- Chairman and CEO
- Holding change
- -1.0%
- Trade date
- Nov 9, 2026
Resmed Q1 2026 Results: Net Income $418M, Up 20.0% YoY
ResMed Inc. reported a net revenue increase to $1.41 billion for the quarter ended September 30, 2026, compared to $1.34 billion in the prior year, driven by Sleep and Breathing Health products. Net income rose to $418.4 million, significantly aided by a $61.8 million gain from the divestment of subsidiaries.
- Key figure
- Net income $418M · +20.0% YoY
Resmed Financial Results
ResMed reported Q1 fiscal year 2027 revenue of $1.4 billion, a 6% increase driven by global demand for sleep and breathing health solutions. The company returned over $1 billion to shareholders through dividends and share repurchases during the quarter, supported by strong free cash flow and the divestiture of MatrixCare.
- Term
- Q1 2027
“We began fiscal year 2027 with a strong first quarter, driven by continued global demand for our sleep and breathing health solutions and ongoing execution across our business. Year over year, we grew core constant currency revenue 7%, expanded non-GAAP gross margin by 50 basis points, and increased non-GAAP earnings per share by 14%.”
Mick Farrell, Resmed’s Chairman and CEO
“Looking ahead to the rest of fiscal year 2027, we will continue to build our core sleep and breathing health businesses by extending the reach of our digital health ecosystem and connecting more of the people worldwide who need care with life-saving treatment delivered right in their own home.”
Mick Farrell, Resmed’s Chairman and CEO
Resmed Global General Counsel Michael J. Rider Sells $102K of Stock
Michael J. Rider, Global General Counsel, sold 400 shares of Resmed Inc at $255.00 a share, worth $102K in total on Oct 23, 2026. Shares held after the trade: 12,318 (-3.1%).
- Value
- $102K
- Shares
- 400
- Price
- $255.00
- Role
- Global General Counsel
- Holding change
- -3.1%
- Trade date
- Oct 23, 2026
Resmed Chairman and CEO Michael J. Farrell Sells $1.13M of Stock
Michael J. Farrell, Chairman and CEO, sold 4,991 shares of Resmed Inc at $226.33 a share, worth $1.13M in total on Oct 7, 2026. Shares held after the trade: 479,803 (-1.0%).
- Value
- $1.13M
- Shares
- 4,991
- Price
- $226.33
- Role
- Chairman and CEO
- Holding change
- -1.0%
- Trade date
- Oct 7, 2026